Indoleamine 2,3-dioxygenase: is it an immune suppressor? - PubMed (original) (raw)

Review

Indoleamine 2,3-dioxygenase: is it an immune suppressor?

Hatem Soliman et al. Cancer J. 2010 Jul-Aug.

Abstract

This article covers what is currently known about the role of the enzyme indoleamine 2,3-dioxygenase (IDO) in cancer-related immunosuppression and the clinical research on IDO inhibitors. A PUBMED search was performed using the terms IDO, indoleamine 2,3-dioxygenase, 1-MT. IDO is an inducible enzyme that catalyzes the rate-limiting first step in tryptophan catabolism. This enzyme is overexpressed in response to IFNgamma in a variety of different malignancies. IDO causes immunosuppression through breakdown of tryptophan in the tumor microenvironment and tumor-draining lymph nodes. The depletion of tryptophan and toxic catabolites renders effector T cells inactive and dendritic cells immunosuppressive. Preclinical data suggest that IDO inhibition can delay tumor growth, enhance dendritic cell vaccines, and synergize with chemotherapy through immune-mediated mechanisms. The lead IDO inhibitor, d-1-methyl-tryptophan (d-1-MT), was selected for phase I trials and seems to have immune modulating activity. Subsequently, another isoform of IDO, IDO2, was discovered and found to be the target of d-1-MT. Multiple single-nucleotide polymorphisms in IDO2 affecting its catalytic activity may serve as a pharmacogenetic predictive biomarker for d-1-MT. The IDO pathway is an important mechanism of tumor-related immunosuppression and blocking it could improve cancer immunotherapy outcomes. Clinical development of d-1-MT and other IDO inhibitors as systemic immunomodulators to be combined with other immune modulators, vaccines, and chemotherapy are ongoing.

PubMed Disclaimer

Figures

FIGURE 1

FIGURE 1

Metabolism of tryptophan. The catabolites in red are directly toxic to T lymphocytes.

FIGURE 2

FIGURE 2

The mechanism of action of IDO. IDO causes decreased cytotoxic T-cell activity and systemic anergy via tryptophan depletion and toxic tryptophan catabolites. Treg indicates T regulatory cell; Trp, tryptophan; pDCs, plasmacytoid dendritic cells.

Similar articles

Cited by

References

    1. Bickels J, Kollender Y, Merinsky O, et al. Coley’s toxin: historical perspective. Isr Med Assoc J. 2002;4:471– 472. - PubMed
    1. Hoption Cann SA, van Netten JP, van Netten C, et al. Spontaneous regression: a hidden treasure buried in time. Med Hypotheses. 2002;58:115–119. - PubMed
    1. Higuchi K, Hayaishi O. Enzymic formation of D-kynurenine from D-tryptophan. Arch Biochem Biophys. 1967;120:397– 403. - PubMed
    1. Yamamoto S, Hayaishi O. Tryptophan pyrrolase of rabbit intestine. D- and L-tryptophan-cleaving enzyme or enzymes. J Biol Chem. 1967;242:5260–5266. - PubMed
    1. Spacek M. Kynurenine in disease, with particular reference to cancer. Can Med Assoc J. 1955;73:198–201. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources